Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Recently, it has been demonstrated that iron overload is associated with the appearance of labile plasma iron (LPI).
LPI is redox active and is rapidly taken up by cells, leading to a rise in the labile iron pool (LIP) and catalyzing generation of reactive oxygen species (ROS), which can lead to cellular damage.
The LPI data are mostly derived from thalassemia iron overload research , however, there are a few data describing LPI and its correlations with the classical iron overload parameters (ferritin, TSAT) in acute anemias such as MDS Therefore we are going to assess LPI in iron overloaded myelodysplastic syndromes (MDS) (low and high risk) and primary myelofibrosis, in order to assess whether it can be used as alternative to the routinely used parameters; TSAT and ferritin levels.
| Condition |
|---|
|
Myelodysplastic Syndrome Primary Myelofibrosis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Assessment of Labile Plasma Iron (LPI) as an Alternative Parameter for Iron Overload in MDS and Primary Myelofibrosis Patients With Iron Overload and Its Correlations With the Classical Iron Overload Parameters. |
- The value of Ferritin,Transferrin Saturation,CRP and LPI at the blood samples [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
The blood samples should be taken at least one week apart from last blood transfusion.
In case of infection or acute inflammation , blood samples should be taken only one week after resolution of these conditions.
| Estimated Enrollment: | 50 |
| Study Start Date: | March 2011 |
| Estimated Study Completion Date: | January 2013 |
| Estimated Primary Completion Date: | January 2013 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
MDS and primary myelofibrosis patients
patients with in iron overloaded MDS patients (low and high risk ), and also patients with primary myelofibrosis. The risk stratification of these patients will be calculated according to the IPSS (International Prognostic Scoring System).
|
Detailed Description:
Approximately 60-80% of patients with myelodysplastic syndromes (MDS) present with symptomatic anemia and 80-90%, of these, will require red blood cell (RBC) transfusions. Excess transfusional iron causes iron overload (IO) which is characterized by elevated serum ferritin (> 1000ng/ml) and transferrin saturation (TSAT > 50%) levels.
Assessment of IO using serum ferritin and TSAT levels is not accurate enough and this is due to changes in serum ferritin and TSAT during any inflammatory condition.
Since serum ferritin is considered as a positive acute phase reactant and therefore inflammatory state can lead to an increase in serum ferritin levels and so does not reflect the exact amount of iron overload.
In contrast TSAT can decrease during inflammation and in addition it follows diurnal variations.The aim of our present study is to asses the levels of LPI in patients with in iron overloaded MDS patients (low and high risk), and also patients with primary myelofibrosis, in order to find out any laboratory correlations between LPI, TSAT and srum ferritin levels.
Methods:
The study will contain 50 patients low+high risk MDS patients and patients with primary myelofibrosis with iron overloaded. The risk stratification of these patients will be calculated according to the WPSS (WHO adapted Prognostic Scoring System)
After ICF (Informed Consent Form) has been signed by the patients the following laboratory tests will be taken once during the study:
- Ferritin (local laboratory)
- Transferrin Saturation (local laboratory)
- CRP (local laboratory)
- LPI (feROS™ eLPI from Aferrix Ltd., Tel- Aviv, Israel)
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
low and high risk MDS patients and primary myelofibrosis patients.The risk stratification of these patients will be calculated according to the WPSS (WHO adapted Prognostic Scoring System)
Inclusion Criteria:
- age > 18 years old
- MDS patients (low and high risk )
Exclusion Criteria:
- age < 18 years old
Contacts and Locations| Contact: Ghoti Hussam, MD | : 970-35028110 | drghoti123@yahoo.com |
| Israel | |
| Wolfson Medical Center | Not yet recruiting |
| Holon,, Israel | |
| Contact: Ghoti Hussam, MD 970-35028110 drghoti123@yahoo.com | |
| Principal Investigator: | Ghoti Hussam, MD | Hematolgy Department of Wolfson Medical Center |
More Information
No publications provided
| Responsible Party: | Dr' Ghoti Hussam, Hematology department of Wolfson Medical Center |
| ClinicalTrials.gov Identifier: | NCT01331603 History of Changes |
| Other Study ID Numbers: | LPI1CTIL |
| Study First Received: | January 18, 2011 |
| Last Updated: | April 7, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Wolfson Medical Center:
|
MDS primary myelofibrosis low+high risk MDS patients patients |
Additional relevant MeSH terms:
|
Primary Myelofibrosis Myelodysplastic Syndromes Preleukemia Iron Overload Myeloproliferative Disorders Bone Marrow Diseases |
Hematologic Diseases Precancerous Conditions Neoplasms Iron Metabolism Disorders Metabolic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013